DaVita (NYSE:DVA) Sets New 1-Year Low – Here’s What Happened

Shares of DaVita Inc. (NYSE:DVA) hit a new 52-week low during trading on Wednesday . The company traded as low as $113.12 and last traded at $113.5920, with a volume of 38268 shares traded. The stock had previously closed at $114.72.

Wall Street Analyst Weigh In

Several analysts have commented on DVA shares. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Barclays decreased their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. TD Cowen lowered their target price on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research note on Monday, November 3rd. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a report on Monday. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus target price of $148.00.

DaVita Trading Down 0.9%

The stock has a 50-day simple moving average of $120.99 and a 200 day simple moving average of $131.09. The company has a market cap of $8.03 billion, a price-to-earnings ratio of 11.69, a PEG ratio of 0.88 and a beta of 1.00.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. During the same period in the prior year, the company posted $2.59 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Institutional Trading of DaVita

Several large investors have recently made changes to their positions in the business. Hantz Financial Services Inc. raised its holdings in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. MAI Capital Management boosted its holdings in DaVita by 23.4% in the second quarter. MAI Capital Management now owns 438 shares of the company’s stock valued at $62,000 after purchasing an additional 83 shares during the last quarter. NewEdge Advisors LLC grew its position in DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Teacher Retirement System of Texas raised its stake in shares of DaVita by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after buying an additional 94 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of DaVita by 34.9% in the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock valued at $59,000 after buying an additional 117 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.